Coinfection with human immunodeficiency virus and hepatitis C virus: Challenges and therapeutic advances - Insights from the Society of Infectious Diseases Pharmacists

Pharmacotherapy

Volumn 31, Issue 4, 2011, Pages 357-368

  Deming, Paulina ^a   McNicholl, Ian R ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antivirals; HCV; Hepatitis C virus; HIV; Human immunodeficiency virus

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BOCEPREVIR; DIDANOSINE; INTERFERON; LAMIVUDINE; LIVER ENZYME; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PLACEBO; RIBAVIRIN; TELAPREVIR; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE PANCREATITIS; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ERADICATION THERAPY; FLU LIKE SYNDROME; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INFECTION RISK; LACTIC ACIDOSIS; LIVER FAILURE; MACULOPAPULAR RASH; MENTAL DISEASE; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MONOTHERAPY; MORTALITY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; SEPSIS; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, PHARMACEUTICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 79953721940     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.4.357     Document Type: Review

References (41)

1. Sherman KE, Rouster SD, Chung RT, Rajiicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the U.S. adult AIDS clinical trials group. Clin Infect Dis 2002;34:831-73.
2. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002;288:199-206.
3. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008;48:353-67.
4. Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-co-infected drug users compared with drug users infected only with hepatitis C virus. J Acquir Immune Defic Syndr 2008;47:221-5.
5. Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008;47:1468-75.
6. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9. (Pubitemid 32709592)
7. Thein H-H, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008;22:1979-91.
8. + cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010;17:400-9.
9. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. Available from http://www.aids info.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 1, 2009.
10. Yacisin K, Maida I, Rios MJ, Soriano V, Nunez M. Hepatitis C virus does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retro 2008;24:935-40.
11. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58(RR-4):1-207. Available from http://aidsinfo.nih.gov/contentfiles/ Adult-OI-041009.pdf. Accessed August 12, 2010.
12. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panel. AIDS 2007;12:1073-89.
13. Ghany MG, Strader DB, Seeff LB, for the American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
14. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82-8. Version 5 updated November 2009. Available from http://www. europeanaidsclinicalsociety.org/guidelines.asp. Accessed November 19, 2009.
15. Martin-Carbonero L, Nunez M, Marino A, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008;22:15-21. (Pubitemid 350294873)
16. Chung RT, Anderson J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9. (Pubitemid 38988594)
17. Torriani FJ, Rodriguez-Torres J, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50. (Pubitemid 38988593)
18. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-36.
19. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA 2004;292:2839-48. (Pubitemid 39628231)
20. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDA Res Hum Retroviruses 2007;23:972-82. (Pubitemid 47492337)
21. Nunez M, Ocampo A, Aguirrebengoa K, et al. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepatitis 2008;15:363-9. (Pubitemid 351473628)
22. Righi E, Beltrame A, Bassetti M, et al. Therapeutic aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort. Infection 2008;36:358-61.
23. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C coinfection. J Acquir Immune Defic Syndr 2008;47:36-49. (Pubitemid 351619367)
24. Fried M. Side effects of therapy for hepatitis C and their management. Hepatology 2002;36:S237-44.
25. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-5.
26. Bani-Sadr F, Lapidus N, Bedossa P, et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008;46:768-74. (Pubitemid 351321564)
27. Mira JA, Gutierrez-Valencia A, de los Santos Gil I, et al. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin Infect Dis 2009;49:e84-91.
28. Bani-Sadr F, Lapidus N, Melchior J-C, et al. Severe weight loss in HIV/HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. J Viral Hepatitis 2008;15:255-60. (Pubitemid 351326906)
29. Craxi A. PEG IFN alfa-2a vs alfa-2b: and the winner is...? J Hepatol 2010;52:133-5.
30. Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, et al. Pegylated interferon alfa-2a plus ribavirin versus pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009;63:1256-63.
31. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alfa-2b versus pegylated interferon alfa-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009;49:22-31.
32. Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008;62:1365-73.
33. Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008;13:953-7.
34. Alvarez D, Dieterich DT, Brau N, et al. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepatitis 2006;13:683-9 (Pubitemid 44401197)
35. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-na?e subjects. J Infect Dis 2008;198:800-7.
36. Berman K, Kwo PY. Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis 2009;13:429-39.
37. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009;50:1709-18.
38. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
39. Kronenberger B, Zeuzem S. Current and future treatment options for HCV. Ann Hepatol 2009;8:103-12.
40. Flores MV, Strawbridge J, Ciaramella G, Corbau R. HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism. Biochimica et Biophysica Acta 2009;1794:1441-8.
41. Suzuki F, Akuta N, Suzuki Y, et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 2009;39:1056-63.